Novel Melanoma Lesion Rx Is a Go There's a new, first-of-its kind treatment for the deadliest type of skin cancer. The US Food and Drug Administration (FDA) recently approved Imlygic (talimogene laherparepvec) to treat melanoma lesions on the skin and in the lymph nodes. “Melanoma is a serious disease that can advance and spread to other parts of the body, where it becomes difficult to treat,” said Karen Midthun, MD, director of the FDA’s Center for Biologics Evaluation and Research, in a press release. “This approval provides patients and health care providers with a novel treatment for melanoma.”